IRVINE, CA--(Marketwire - November 17, 2010) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a novel compounds biotech company focused on research and development to regress atherosclerotic plaque, announced that Paul DiPerna, CTO and Founder of Tandem Diabetes Care, has been named to the Board of Directors of AtheroNova Inc.
"As a leading health science innovator, Paul DiPerna brings a wealth of experience in shepherding new technologies through the development process to AtheroNova," stated Thomas W. Gardner, CEO of AtheroNova. "We welcome Paul to our Board and look forward to working together as we develop AtheroNova's atherosclerosis regression technology."
Paul DiPerna is the Founder, Chief Technical Officer and a Board Member of Tandem Diabetes Care, a venture backed company that has raised $68 million. Tandem is developing technology to be used in the care of diabetes. In this venture Paul has over 18 patents issued and in process.
Prior to forming Tandem, Mr. DiPerna worked at Baxter Healthcare for 14 years where he held progressive management positions as a Technologist for cell separation systems, Program Manager of the largest and complex system Baxter had undertaken, Director of Business Development in the corporate technology group creating new technologies and integrating acquisitions into Baxter and as the General Manager of Digital Dental Sciences. He had 10 patents issued while at Baxter.
Mr. DiPerna was also a Senior VP of Technology and Operations at Hepahope, a startup developing liver dialysis systems for end stage liver failure patients prior to funding of Tandem.
Mr. DiPerna received a Masters in Engineering Management from Northeastern University and a BS in Mechanical Engineering from the University of Massachusetts Lowell. He is a member of the American Diabetes Association and the American Society of Clinical Oncology.
AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the value of Mr. DiPerna's appointment to AtheroNova's board, and the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.